199 related articles for article (PubMed ID: 37310540)
1. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
Breast Cancer Res Treat; 2023 Aug; 201(1):105-115. PubMed ID: 37310540
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract][Full Text] [Related]
4. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
7. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
8. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
10. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
12. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Alvarez A; Bernal AM; Anampa J
Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
[TBL] [Abstract][Full Text] [Related]
15. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
Harbeck N; Bartlett M; Spurden D; Hooper B; Zhan L; Rosta E; Cameron C; Mitra D; Zhou A
Future Oncol; 2021 Jun; 17(16):2107-2122. PubMed ID: 33663223
[No Abstract] [Full Text] [Related]
18. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract][Full Text] [Related]
19. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
[TBL] [Abstract][Full Text] [Related]
20. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
